Intraoperative gamma detection of 125I-lanreotide in women with primary breast cancer

What Was Tested

The paper reports a study of Somatostatin and Lanreotide, published as a clinical trial.

Somatostatin receptors are present in most human breast cancers.

The researchers performed a pilot trial of intraoperative tumor-gamma detection using the radiolabeled somatostatin analog 125I-lanreotide in 13 women with 14 primary breast carcinomas.

Who Took Part

According to the abstract, 13 women were involved.

The age groups tagged for this paper are middle-aged adults and older adults, women only.

All patients were given 125I-lanreotide intravenously before surgery.

Patients underwent lumpectomy, and postresection margins were evaluated with the gamma probe.

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger Somatostatin study would be practical.

Axillary dissection specimens were evaluated ex vivo.

What Was Measured

The researchers performed a pilot trial of intraoperative tumor-gamma detection using the radiolabeled somatostatin analog 125I-lanreotide in 13 women with 14 primary breast carcinomas.

Topics PubMed links to this paper include Breast Neoplasms, Intraoperative Period, Iodine Radioisotopes, Lymph Node Excision, Lymph Nodes, Mastectomy, Segmental and Peptides, Cyclic.

What This Means in Plain Language

The paper is a pilot study of Somatostatin and Lanreotide in 13 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1999 (Annals of surgical oncology), a journal based in United States.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.